Literature DB >> 6175399

Inhibition of mitochondrial protein synthesis during early stages of aflatoxin B1-induced hepatocarcinogenesis.

N K Bhat, J K Emeh, B G Niranjan, N G Avadhani.   

Abstract

Experiments were designed to determine the in vivo effects of a single 6-mg/kg dose aflatoxin B1 on rat liver mitochondrial transcription and translation processes. With the use of intact hepatocytes and also a highly active mitoplast system for incorporation, it was observed that both mitochondrial transcription and translation activities are inhibited progressively even after 24 hr of carcinogen administration. Electrophoretic patterns of mitochondrial translation products show some qualitative changes during early periods of carcinogen administration. At later stages (greater than 12 hr), however, there is a general inhibition of many of the products, although by this time there is a qualitative and quantitative recovery in the synthesis of mitochondrial proteins imported from the cytoplasm. These results, along with the data showing considerably high levels of aflatoxin B1 binding to mitochondrial DNA suggest that mitochondrial genetic system is one of the direct targets during experimental carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175399

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

Review 1.  Mitochondrial ribosomes in cancer.

Authors:  Hyun-Jung Kim; Priyanka Maiti; Antoni Barrientos
Journal:  Semin Cancer Biol       Date:  2017-04-23       Impact factor: 15.707

2.  Tumor-associated mutations of rat mitochondrial transfer RNA genes.

Authors:  M Taira; E Yoshida; M Kobayashi; K Yaginuma; K Koike
Journal:  Nucleic Acids Res       Date:  1983-03-25       Impact factor: 16.971

3.  Detection of mycotoxins in patients with chronic fatigue syndrome.

Authors:  Joseph H Brewer; Jack D Thrasher; David C Straus; Roberta A Madison; Dennis Hooper
Journal:  Toxins (Basel)       Date:  2013-04-11       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.